Publication Adhikari P, Int J Infect Dis (2022)
Funding: Not reported/unclear
Conflict of interest: *
Multicenter / Nepal |
Follow-up duration (days): *
Initial dose: 200 mg by IV on day 1 -Maintenance dose: 100 mg by IV daily from day 2 until day 5.
Initial dose: 1800 mg orally twice on day 1 -Maintenance dose: 800 mg orally 2 times a day from day 2 until day 10.
|Characteristics of participants|
Mean age : NR
Severity : Mild: n=0 / Moderate: n=20 / Severe: n=0 Critical: n=0
Number of vaccinated participants: NR
|In the register|
Clinical improvements in mild cases [Time Frame: 5 day]: Time to clinical improvements is defined as recovery in two out of the three common symptoms that includes fever (body temperature more than 99.5 degrees F), cough, and headache/malaise (scored more than 3 in a pain likert scale of 1 to 10).
|In the report|
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
|General comment||Only the published abstract and registry were used in data extraction and risk of bias assessment. There was no protocol or statistical analysis plan available. The table seems to have a typographical error - the 9 "Placebo" participants were extracted as the Remdesivir arm, according to the text. This was a preliminary data analysis.|